Do Inhaled B2-Agonists have an Ergogenic Potential in Non-Asthmatic Competitive Athletes?
- 631 Downloads
The prevalence of asthma is higher in elite athletes than in the general population. The risk of developing asthmatic symptoms is the highest in endurance athletes and swimmers. Astma seems particularly widespread in winter-sport athletes such as cross-country skiers. Asthmatic athletes commonly use inhaled β2-agonists to prevent and treat asthmatic symptoms. However, β2-agonists are prohibited according to the Prohibited List of the World Anti-Doping Agency. An exception can be made only for the substances forrnoterol, salbutamol, sahneterol and terbutaline by inhalation, as long as a therapeutic use exemption has been applied for and granted. In this context, the question arises of whether β2-agonists have ergogenic benefits justifying the prohibition of these substances
In 17 of 19 randomised placebo-controlled trials in non-asthmatic competitive athletes, performance-enhancing effects of the inhaled β2-agonists formoterol, salbutarnol, sahneterol and terbutaline could not be proved. This is particularly true for endurance performance, anaerobic power and strength performance. In three of four studies, even supratherapeutic doses of salbutarnol (800–1200μg) had no ergogenic effect. In contrast to inhaled β2-agonists, oral administration of salbutarnol seems to be able to improve the muscle strength and the endurance performance. There appears to be no justification to prohibit inhaled β2-agonists from the point of view of the ergogenic effects.
KeywordsSalbutamol Salmeterol Terbutaline Montelukast Formoterol
No sources of funding were used to assist in the preparation of this article. The author has no conflicts of interest that are directly relevant to the content of this article.
- 1.World Anti-Doping Agency. The prohibited list [online]. Available from URL: http://www.wada-ama.org [Accessed 2006 Dec 13]
- 38.Rundell KW, Spiering BA, Baumann JM, et al. Effects of montelukast on airway narrowing from eucapnic voluntaryhyperventilation and cold air exercise. Br J Sports Med 2005;Google Scholar
- 41.Valero A, Garrido E, Malet A, et al. Exercise-induced asthma prophylaxis in athletes using inhaled nedocromil sodium. AIlergol Immunopathol 1996; 24: 81–6Google Scholar
- 72.Strømme SB, Boushel R, Ekblom B, et al. Cardiovascular and respiratory aspects of exercise: endurance training. In: KjaerM, Krogsgaard M, Magnusson M, et al., editors. Textbook of Sports Medicine. Oxford, UK: Blackwell Science, 2003: 11–29Google Scholar
- 74.Corrigan B, Kazlauskas R. Medication use in athletes selected for doping control at the Sydney OIympics (2000). Clin J SportMed 2003; 13: 33–40Google Scholar
- 75.Kindermann W. The problem of doping and current doping list. Dtsch Z Sportrned 2004; 55: 90–5Google Scholar